"Although omalizumab is not a cure, it's a major step forward for patients as the first monoclonal antibody or biologic therapy to become FDA-approved to treat food allergy." — Dr. Brian Vickery

Is omalizumab set to change the food allergy landscape? And how should clinicians use it in practice? On this episode of The Allergist, Dr. Mariam Hanna sits down with Dr. Brian Vickery, professor of pediatrics and chief of the Division of Allergy and Immunology at Emory University, to break down what allergists need to know about this new FDA-approved biologic for food allergies.

• What makes omalizumab a milestone treatment? The first FDA-approved biologic for food allergies, covering multiple allergens and all age groups from one year and up.

• How does it work? A deep dive into its mechanism, from intercepting free IgE to its broader immunological effects.

• The implications of the OUTMATCH trial: What the numbers really say about efficacy across different foods, including why cashew results looked weaker than peanut but might just be an artifact of study design.

• Who should consider it? A practical look at patient selection—where omalizumab might be an ideal option and where OIT or other strategies may still be preferable.

• Where do we go from here? The future of biologics in food allergy treatment, including whether other monoclonals like dupilumab could play a role down the line.

Join us as we unpack the data, the clinical applications, and the questions still left unanswered.

Visit the Canadian Society of Allergy and Clinical Immunology
Find an allergist using our helpful tool
Find Dr. Hanna on X, previously Twitter, @PedsAllergyDoc or CSACI @CSACI_ca
The Allergist is produced for CSACI by PodCraft Productions